Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic TM Antisense ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide (ASO) therapy targeting a single, undisclosed central nervous system ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Morningstar brands and products Company Portfolio ...

In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million. Alloy will also be eligible to receive discovery, development ...

The region has seen several young companies rocket to success in recent years, and these 10 startups look ready to fire up ...

Privately-held US biotech Alloy Therapeutics has announced a target specific collaboration and license agreement for the use of its novel and proprietary anticlastic antisense platform with French ...